A challenging session for Medicenna as market pressures weigh down its stock.
Medicenna Therapeutics Corp experienced a notable decline in its stock price during yesterday’s trading session, closing down 3.53% at CA$0.41. This drop reflects ongoing challenges in the biotech sector, particularly for smaller firms like MDNA.TO.
Investor takeaway: Investors should remain cautious with Medicenna, as its recent performance highlights the volatility and risks associated with small-cap biotech stocks.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.38M
52W high
$1.97
52W low
$0.34
1W change
+1.25%
Beta
1.96
Analyst Price Targets
Based on analyst covering MDNA · as of Sep 17, 2026
Wall Street analysts forecast MDNA stock price to rise 690.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+690.1% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
64.9%
Annualized
90-Day Vol
57.0%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.41 | C$0.32 – C$0.51 |
| 60 trading days | C$0.41 | C$0.30 – C$0.56 |
| 90 trading days | C$0.41 | C$0.27 – C$0.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
CA$0.41 Closing Price
Medicenna's market cap now stands at approximately CA$37.84 million, reflecting investor caution amidst recent performance.
Bull case
Despite the recent setback, Medicenna's innovative pipeline, including promising therapies like MDNA11, has the potential to drive future growth if clinical results meet investor expectations.
Bear case
The decline in stock price, along with a lack of significant news to boost investor sentiment, raises concerns about the company’s ability to maintain momentum in a competitive market.
Market Reaction and Context
Advertisement
Medicenna's 3.53% drop yesterday is part of a broader trend affecting small-cap biotech stocks, which often face increased volatility. Without significant news to counteract this downward pressure, investor sentiment has remained cautious.
Company Developments
Although Medicenna recently announced its participation in upcoming industry conferences and reported financial results, these updates did not lead to positive market momentum. Investors may be looking for more substantial developments or clinical results to regain confidence.
Looking Ahead
As Medicenna moves forward, the focus will be on its upcoming presentations and potential breakthroughs in its clinical trials. Investors should keep a close eye on these developments, as they could significantly impact the stock's trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
